SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Nobivac Solvent

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 1 ml dose contains:

Excipients:

Qualitative composition of excipients and other constituents
Potassium dihydrogen phosphate
Disodium phosphate
Water for injections

A clear colourless solution.

3. CLINICAL INFORMATION

3.1 Target species

Cats and dogs.

3.2 Indications for use for each target species

Solvent for reconstitution of lyophilisates in the Nobivac vaccine range authorised for use with Nobivac Solvent.

3.3 Contraindications

Any contraindications specified for the vaccine product for which the Nobivac Solvent is used for reconstitution will apply.

3.4 Special warnings

None.

3.5 Special precautions for use

Special precautions for safe use in the target species:
No special precautions are required for handling the solvent however any recommendations specified for the vaccine product for which Nobivac Solvent is used for reconstitution will apply.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
After reconstitution: Any recommendations specified for the vaccine product for which Nobivac Solvent is used for reconstitution will apply.

Special precautions for the protection of the environment:
Not applicable.

3.6 Adverse events

Any adverse events specified for the vaccine product for which Nobivac Solvent is used for reconstitution will apply.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Any recommendations specified for the vaccine product for which Nobivac Solvent is used for reconstitution will apply.

3.8 Interaction with other medicinal products and other forms of interaction

Nobivac Solvent should only be used as a solvent for the reconstitution of lyophilisates in the Nobivac vaccine range authorised to be used with Nobivac Solvent.
No information is available on the safety and efficacy when used with any other veterinary medicinal product. Any recommendations specified for the vaccine product for which Nobivac Solvent is used for reconstitution will apply.

3.9 Administration routes and dosage

The instructions supplied with the vaccine product should be read carefully before using the Nobivac Solvent.
The contents of one vial (1 ml) of Nobivac Solvent should be transferred aseptically into the vial of freeze-dried vaccine immediately prior to use. Care should be taken to ensure that the freeze-dried powder plug has fully dissolved. Sterile equipment should be used for administration.

Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use chemicals such as disinfectant or spirit to disinfect the skin prior to inoculation.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Any recommendations specified for the vaccine product for which Nobivac Solvent is used for reconstitution will apply.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. IMMUNOLOGICAL INFORMATION

4.1 ATCvet code: QV07AB.

The solvent does not contain active ingredients.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

For use only with lyophilisates in the Nobivac vaccine product range which are authorised to be reconstituted with Nobivac Solvent. Do not mix with any other veterinary medicinal product.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: use immediately.

5.3 Special precautions for storage

Do not store above 25 °C.
Do not freeze.
Protect from light.

5.4 Nature and composition of immediate packaging

Clear, Glass Type I (Ph. Eur) single vials with halogenobutyl rubber stopper (Ph. Eur.) and aluminium crimp cap.

Pack size:
Cardboard boxes with 10 x 1 ml or 50 x 1 ml vials.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Intervet International B.V.

7. MARKETING AUTHORISATION NUMBER

Vm 06376/4126

8. DATE OF FIRST AUTHORISATION

28 October 2005

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

November 2025

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription.

Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.

Gavin Hall

Approved 22 February 2026